Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
This article was originally published in The Gray Sheet
Executive Summary
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months
You may also be interested in...
St. Jude ICD Segment Improves 53% In Q2 Despite Competition From CRT
St. Jude's pacing and ICD businesses have not been significantly affected by the recent launch of cardiac resynchronization devices from competitors Medtronic and Guidant
St. Jude ICD Segment Improves 53% In Q2 Despite Competition From CRT
St. Jude's pacing and ICD businesses have not been significantly affected by the recent launch of cardiac resynchronization devices from competitors Medtronic and Guidant
Abbott Gains Access To Celera R&D For Infectious Disease Assays
U.S. clinical lab evaluation of Celera Diagnostics' analyte-specific reagent hepatitis C test by year-end will be among the early milestones of the Applera unit's R&D and marketing agreement with Abbott